Literature DB >> 12297328

Manipulation of immune responses by Epstein-Barr virus.

Victor Levitsky1, Maria G Masucci.   

Abstract

Epstein-Barr virus (EBV) infects and persists for life in the majority of the human population. Persistence is achieved through a combination of strictly regulated programs of latent infection in B-cells and chronic reactivation of virus replication in lymphoid tissue and mucosal surfaces. The resulting multiple patterns of virus-host interaction have selected unique strategies of immune escape. T-cell mediated immunity plays a central role in the control of EBV latency and several immune escape mechanism that protect the virus at this stage of its life circle have been characterized in details. In contrast, the contribution of innate immunity and the immune regulation of productive infection are largely unexplored areas that may yield important clues on the establishment and maintenance of EBV persistence. This review summarizes well known and emerging mechanisms of EBV immune escape that may reveal new strategies of immunoregulation and promote new approaches to the prophylaxis and treatment of EBV associated diseases.

Entities:  

Mesh:

Year:  2002        PMID: 12297328     DOI: 10.1016/s0168-1702(02)00121-1

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  11 in total

1.  Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Raquel Gomez; Bianca Heemskerk; Mireille Toebes; Maureen M Mullen; Theodore S Jardetzky; Richard Longnecker; Marco W Schilham; Tom H M Ottenhoff; Jacques Neefjes; Ton N Schumacher; Lindsey M Hutt-Fletcher; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

2.  HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays.

Authors:  Jennifer D Stone; Walter E Demkowicz; Lawrence J Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-23       Impact factor: 11.205

3.  Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Sinéad Keating; Raquel Gomez; Kees L M C Franken; Tom H M Ottenhoff; Melanie Spriggs; Ton N Schumacher; Lindsey M Hutt-Fletcher; Martin Rowe; Emmanuel J H J Wiertz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  Scherrer and Jost's symposium: the gene concept in 2008.

Authors:  Donald R Forsdyke
Journal:  Theory Biosci       Date:  2009-08-21       Impact factor: 1.919

5.  Heat shock protein 90 expression in Epstein-Barr virus-infected B cells promotes gammadelta T-cell proliferation in vitro.

Authors:  Maria Kotsiopriftis; Jerome E Tanner; Caroline Alfieri
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

6.  Immune regulation and evasion of Mammalian host cell immunity during viral infection.

Authors:  B M Pratheek; Soham Saha; Prasanta K Maiti; Soma Chattopadhyay; Subhasis Chattopadhyay
Journal:  Indian J Virol       Date:  2013-03-15

7.  Human papillomavirus type 16 E6* induces oxidative stress and DNA damage.

Authors:  Vonetta M Williams; Maria Filippova; Valery Filippov; Kimberly J Payne; Penelope Duerksen-Hughes
Journal:  J Virol       Date:  2014-04-02       Impact factor: 5.103

8.  Epstein-Barr virus-encoded dUTPase enhances proinflammatory cytokine production by macrophages in contact with endothelial cells: evidence for depression-induced atherosclerotic risk.

Authors:  W James Waldman; Marshall V Williams; Stanley Lemeshow; Philip Binkley; Denis Guttridge; Janice K Kiecolt-Glaser; Deborah A Knight; Katherine J Ladner; Ronald Glaser
Journal:  Brain Behav Immun       Date:  2007-09-12       Impact factor: 7.217

Review 9.  Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders.

Authors:  Debora Martorelli; Elena Muraro; Anna Merlo; Riccardo Turrini; Damiana Antonia Faè; Antonio Rosato; Riccardo Dolcetti
Journal:  Clin Dev Immunol       Date:  2012-01-29

10.  Dynamics of the major histocompatibility complex class I processing and presentation pathway in the course of malaria parasite development in human hepatocytes: implications for vaccine development.

Authors:  Jinxia Ma; Stefanie Trop; Samantha Baer; Elian Rakhmanaliev; Zita Arany; Peter Dumoulin; Hao Zhang; Julia Romano; Isabelle Coppens; Victor Levitsky; Jelena Levitskaya
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.